Firsocostat is under clinical development by Gilead Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Firsocostat’s likelihood of approval (LoA) and phase transition for Cirrhosis took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Firsocostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Firsocostat overview

Firsocostat (GS-0976 (NDI-010976)) is under development for the treatment of non-alcoholic steatohepatitis, Non Alcoholic Fatty Liver Disease (NAFLD), cirrhosis, and liver fibrosis. It is administered orally as a tablet. The drug candidate acts by targeting the enzyme acetyl-CoA carboxylase (ACC). It is based on computational technologies. It was also under development for  non-alcoholic fatty liver disease, obesity, dyslipidemia, type 2 diabetes, hepatocellular carcinoma.

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Quick View Firsocostat LOA Data

Report Segments
  • Innovator
Drug Name
  • Firsocostat
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.